Imbria Pharmaceuticals key facts
as of Oct 2026- Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders.
- Imbria Pharmaceuticals is valued at approximately $131.7M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $151.9M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($66.7M) in Dec 2025.
- Notable investors include RA Capital Management, Catalio Capital Management, SV Health Investors, Deep Track Capital, AN Ventures — 9 tracked in total.
- Imbria Pharmaceuticals has filed 2 Form Ds with the SEC since 2020, most recently Apr 2025 ($59.2M sold to 8 investors).
- Status: Privately Held (backing).
Valued at $131.7M at its later-stage round, Dec 2025. Nothing has traded since.
- ·Watch Imbria Pharmaceuticals: the Monday email on marks, rounds and moves
Imbria Pharmaceuticals funding rounds
2 roundsImbria Pharmaceuticals valuation
Imbria Pharmaceuticals was valued at $132 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Imbria Pharmaceuticals raised?
Imbria Pharmaceuticals has raised $152 million in total; 2 of its rounds are on record. The largest on record was a $66.7 million Series B in Dec 2025.
Imbria Pharmaceuticals has filed 2 Form Ds with the SEC since 2020, most recently in Apr 2025 ($59.2 million sold to 8 investors).
Imbria Pharmaceuticals investors
9 investors are on record for Imbria Pharmaceuticals, including RA Capital Management, Catalio Capital Management, SV Health Investors and Deep Track Capital. The Series B in Dec 2025 drew 6 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Alchemab Therapeutics ($138 million), Tahoe ($131 million) and Vivace Therapeutics ($125 million).
About Imbria Pharmaceuticals
Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders. The company focused on restoring or improving the cell's ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction, enabling healthcare providers to provide medicine by altering the cellular metabolism and mitochondrial function.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 10
- Website
- imbria.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.